Stopping Ozempic or Mounjaro: will the weight come back? What 2026 research says

Does weight come back after you stop Ozempic or Mounjaro?

On average, yes: at least some of it can. Medicines such as Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) work largely by changing appetite and fullness signals. When treatment ends, those effects fade, hunger tends to return, and part of the lost weight can come back.

This does not mean you lack willpower or that the treatment “failed”. Obesity is a chronic health condition in which biology plays a large part. Once the medicine is gone, the mechanisms that regulate body weight come back into play. In that respect it resembles many treatments for chronic conditions, where the benefit tends to track with the treatment itself. The difference is that weight is visible and loaded with judgment, so regain can feel like personal failure. It isn’t.

A 2026 systematic review and meta-analysis in the BMJ looked at exactly this question, and weight regain after stopping was the typical finding. The figures below are group averages, not a forecast for any one person.

Why can weight come back after stopping?

Researchers don’t point to a single cause. Three things are commonly discussed:

• Appetite and fullness change. GLP-1-based drugs act on hunger and satiety. When that effect is gone, you may feel hungry more often or eat larger portions without trying to.
• Habits can slip. Eating and activity patterns built during treatment are harder to hold when the medicine’s help is removed. Daily energy intake can creep back up, so a maintenance plan that only covers the on-medication period leaves a gap.
• The body responds to weight loss. After losing weight, energy needs can fall, and in some people hunger and fullness signals shift as well. Together these can make a lower weight harder to hold.

What does the research show?

The BMJ meta-analysis (West and colleagues, 2026) pooled 37 studies and 9,341 participants. After weight-management medication was stopped, people regained on average about 0.4 kg per month. In the analysis of semaglutide and tirzepatide, the more effective newer drugs, the average was about 0.8 kg per month.

Extrapolating those rates, the authors modelled a return to starting weight in roughly 1.5 to 2 years after stopping. They also projected that cardiometabolic markers (HbA1c, fasting glucose, blood pressure, cholesterol and triglycerides) drift back to baseline within about 1.4 years.

Three caveats matter when you read those numbers:

• They are modelled. Most of the included studies followed people for only 4 to 52 weeks, so the long-range projections are estimates built on short follow-up.
• They are averages. Starting weight, how much you lost, how long you were on treatment, your circumstances and your support afterwards can all change your own result. Averages do not mean everyone regains everything.
• Behavioural support was not shown to help here. The review found no evidence that behavioural support during treatment improved weight maintenance after stopping. That is not proof such support is pointless; it means we don’t yet have a proven way to lock in the loss, which is a good reason to plan the after-treatment phase deliberately.

What should you plan before stopping?

If stopping or switching is on the table, build the plan with your prescriber first. Questions worth settling together:

• Why are you stopping? Cost, side effects, supply, reaching a goal and a change in health all lead to different plans, and there may be alternatives to consider. If you are planning a pregnancy, raise it before you try to conceive, because these medicines are not used during pregnancy.
• What is your maintenance goal? Focus not only on a target weight but on how you’ll stay there, and how often you’ll check in.
• Is your eating pattern sustainable? A plan you can keep for years beats a strict one you can’t.
• How will you look after muscle? A 2025 joint advisory from ACLM, ASN, OMA and TOS on nutrition during GLP-1 therapy stresses adequate protein and resistance training to protect muscle and function (see our muscle loss guide). These habits support your health; they are not a proven way to prevent regain.
• How will you track your trend? Weighing regularly makes an upward drift visible early, while the plan is still easy to adjust.
• What about diabetes? If you take the drug partly for blood sugar, changing treatment can change your glucose levels, so monitoring matters.

Does tapering the dose prevent regain?

Reducing the dose gradually before stopping has not been shown to prevent weight regain. So there is no reason to assume a slow step-down protects you, and no reason to improvise one.

Please don’t taper, change your dosing interval, stop or restart on your own. Whether to continue, change or end treatment depends on why you use the medicine, any side effects, cost, your health goals and the alternatives available. That is a decision to make with your prescriber.

What should you monitor after stopping?

The follow-up plan shouldn’t end when the prescription does. Because the BMJ analysis projects blood pressure, cholesterol and blood-sugar markers drifting back as well, it is worth looking beyond the scale:

• Weight and waist trend, ideally measured the same way on a regular schedule.
• Blood sugar, especially if you have diabetes. Your clinician decides how often to check.
• Appetite. Markedly stronger hunger is useful information to share.
• Everything the scale can’t see: how well you are eating, physical performance, sleep and day-to-day movement.

Judge the trend over weeks, not days. Daily weight moves with fluid, meals and hormones, so one high reading is not regain. But talk to a healthcare professional if your appetite increases markedly, your weight keeps trending upward, or your blood sugar control gets worse.

The measured takeaway

Weight regain after stopping a GLP-1 drug is common and supported by good evidence, but it does not mean everyone will regain everything they lost. The most useful move is a maintenance plan that covers life after the prescription, made with your doctor and watched through more than the scale.

If the scale does start to creep up after you stop, treat it as a reason to contact your care team early, not as a reason for self-blame. Earlier conversations leave more options open.

A regular weigh-in is the simplest early-warning system, and GLPMate’s GLP-1 weight tracker turns scattered readings into a trend you can show your clinician. This article is educational only, not medical advice. Don’t stop, change or restart any medicine without your doctor.

FAQ

FAQ

Will I gain weight back after stopping Ozempic or Mounjaro?

Regain is the typical finding on average, though not everyone regains all of it. A 2026 BMJ meta-analysis of 37 studies found people regained about 0.4 kg per month after stopping weight-management drugs, and about 0.8 kg per month for semaglutide and tirzepatide. Regain is not a sign of failure: obesity is a chronic condition with strong biological drivers.

How fast is weight regained after stopping?

In the 2026 BMJ meta-analysis, about 0.4 kg per month on average across weight-management drugs and about 0.8 kg per month for semaglutide and tirzepatide. Modelled projections put a return to starting weight at roughly 1.5–2 years, but most included studies followed people for only 4–52 weeks, so treat that long-range figure as an estimate.

Does tapering the dose prevent regain?

Stepping down gradually has not been shown to prevent weight regain. Don't taper, change your dosing interval, stop or restart on your own. Whether to continue, change or end treatment is a decision for you and your prescriber, based on why you take the drug, side effects, cost, health goals and alternatives.

What should I plan with my doctor before stopping?

Agree on why you're stopping and what the alternatives are, set a maintenance goal and a follow-up schedule (weight, waist and, if you have diabetes, blood sugar), and plan how you'll look after muscle with adequate protein and resistance exercise. Also agree what should prompt an earlier visit, such as markedly stronger appetite, a steady upward weight trend or worsening glucose readings.